Clinical trials: Chronic Obstructive Pulmonary
Pulmonary Disease, Chronic Obstructive
QTc Study GSK573719+GW642444
This is a randomized, placebo controlled, four period incomplete block,crossover thorough QT study to estimate the effect of repeat dose GSK573719/GW642444M (Vilanterol) combination and GSK573719 monotherapy on the QTc interval…
- Trial name
- NCT01521377
- Testing
- Moxifloxacin, GSK573719/Vilanterol 125/25mcg, GSK573719
- Where
- United Kingdom
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease.
- Trial name
- KRONOS (NCT02497001)
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI (PT003) 14.4/9.6 μg, BFF MDI (PT009) 320/9.6 μg
- Where
- 190 sites in United States, Canada and 2 more
- Volunteers
- 1,902 people
- Sponsor
- Pearl Therapeutics, Inc.
Pulmonary Disease, Chronic Obstructive
BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis
The main objective of the current trial is to investigate safety, tolerability and pharmacokinetics of BI 113608 in COPD patients with symptoms of chronic bronchitis.
- Trial name
- NCT01958008
- Testing
- BI 113608 high dose b.i.d., BI 113608 low dose b.i.d.
- Where
- 6 sites in Germany
- Volunteers
- 84 people
- Sponsor
- Boehringer Ingelheim
COPD
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective compared to the control drug.
- Trial name
- NCT00215384
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Dey
COPD, Emphysema
Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3
The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea…
- Trial name
- BREATHE-3 (NCT06891755)
- Testing
- Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM)
- Where
- 23 sites in United States, Austria and 3 more
- Volunteers
- 250 people
- Sponsor
- Apreo Health, Inc.
Pulmonary Disease, Chronic Obstructive
A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)
A retrospective analysis study in COPD patients for an exact follow-up period of 12 months (in subgroup analyses: 24 and 36 months); censoring of patients will only be done in case a patient died during the respective follow-up…
- Trial name
- NCT04097223
- Where
- Germany
- Volunteers
- 17,464 people
- Sponsor
- Boehringer Ingelheim
Myelodysplastic Syndromes
Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes
Evaluate the safety and efficacy of oral azacitidne (CC-486) twice daily (BID) in subjects with myelodysplastic syndromes who failed to achieve an objective response post injectable hypomethylating agent (iHMA) treatment Reason…
- Trial name
- NCT02281084
- Testing
- Oral Azacitidine, Durvalumab
- Where
- 89 sites in United States, Australia and 8 more
- Volunteers
- 65 people
- Sponsor
- Celgene
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
This study was designed to investigate the efficacy and safety of NVA237, a long-acting muscarinic antagonist, in patients with moderate to severe COPD.
- Trial name
- NCT01119950
- Testing
- NVA237 12.5 µg once daily, NVA237 25.0 µg once daily, NVA237 12.5 µg twice daily
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 388 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 Trial of JKN2401 Injection in COPD
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous JKN2401 Injection in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT07330310
- Testing
- JKN2401 Injection
- Volunteers
- 888 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Pulmonary Disease, Chronic Obstructive
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Study to investigate the dose-dependent bronchodilator effect and the safety of single inhalation doses of BEA 2180 inhaled via Respimat® compared to placebo in patients with stable Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT02242279
- Testing
- BEA 2180 BR, Tiotropium
- Volunteers
- 37 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices
This is a randomised, open-label, placebo, crossover, multicentre study with a single visit. The study will comprise five sub-studies.
- Trial name
- NCT02184624
- Testing
- ELLIPTA, DISKUS/ACCUHALER, MDI
- Where
- 8 sites in Netherlands, United Kingdom
- Volunteers
- 569 people
- Sponsor
- GlaxoSmithKline
Chronic Graft Versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD. The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically…
- Trial name
- ROCKnrol-1 (NCT06143891)
- Testing
- Belumosudil, Prednisone, Prednisolone
- Where
- 151 sites in United States, Argentina and 22 more
- Volunteers
- 260 people
- Sponsor
- Sanofi
Pulmonary Disease, Chronic Obstructive (COPD)
Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to compare in COPD patients naïve to DPIs, the perception of the Breezhaler® and Ellipta® devices' feedback mechanisms evaluated using a preference questionnaire.
- Trial name
- Advantage (NCT02551224)
- Testing
- Patient preference questionnaire
- Where
- 10 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
COPD, Comorbidities and Coexisting Conditions
Pragmatic Assessment of the NuvoAir Clinical Service in the Management of Patients With Chronic Obstructive Pulmonary Disease
This is a 12 month study of up to 500 people with COPD to determine if the NuvoAir clinical service leads to lower rates of severe COPD exacerbations, hospitalizations, emergency room visits, and total cost of care compared to a…
- Trial name
- PROMISE (NCT05955482)
- Testing
- NuvoAir Clinical Service
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- NuvoAir Medical PC
Asthma
Study of Daclizumab in Patients With Chronic, Persistent Asthma
The purpose of the study is to evaluate an investigational medication to treat chronic persistent asthma. The research is being conducted at up to 22 clinical research sites in the US and is open to both men and women ages 18 to…
- Trial name
- NCT00028288
- Testing
- Daclizumab
- Where
- 18 sites in United States
- Volunteers
- 120 people
- Sponsor
- Facet Biotech
Chronic Graft-Versus-Host Disease (cGVHD)
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
The purpose of this study is to determine if vimseltinib is safe, tolerable and works effectively to treat adults with active moderate to severe cGVHD.
- Trial name
- NCT06619561
- Testing
- Vimseltinib
- Where
- 26 sites in United States
- Volunteers
- 48 people
- Sponsor
- Deciphera Pharmaceuticals, LLC
Pulmonary Disease, Chronic Obstructive
A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients
This study will involve the use of a new medicine called GW642444 being developed for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00702910
- Testing
- GW642444, Magnesium Stearate
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Chronic, Intractable Back Pain and/or Leg Pain
Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic Pain
This is a single-center, prospective, non-randomized exploratory study in subjects with chronic, intractable back pain and/or leg pain per the center's routine practice.
- Trial name
- MED (NCT06897280)
- Testing
- SCS Device Program Setting
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nevro Corp
Pulmonary Disease, Chronic Obstructive
12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
Determine the effect of 12-week treatment with inhaled tiotropium bromide on lung function and static lung volumes, correlate this effect with dyspnoea in COPD patients.
- Trial name
- NCT02172378
- Testing
- Tiotropium inhalation capsules
- Volunteers
- 116 people
- Sponsor
- Boehringer Ingelheim
COPD (Chronic Obstructive Pulmonary Disease)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial of JKN2403 in COPD
The goal of this clinical trial is to learn if drug JKN2403 works to treat moderate-to-severe COPD in adults. It will also learn about the safety and pharmacokinetic characteristics of drug JKN2403.
- Trial name
- COPD (NCT07351734)
- Testing
- JKN2403 Tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.